Celecoxib

Licensed by Pfizer Catalog No.S1261 Synonyms: SC 58635

Celecoxib Chemical Structure

Molecular Weight(MW): 381.37

Celecoxib is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.

Size Price Stock Quantity  
USD 97 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 12 Publications

5 Customer Reviews

  • Tumors were resected from mice 10 days after orthotopic inoculation of 4T1-Luc2 cells, and hydrogels loaded with the following payloads were evaluated: anti–PD-1, anti-CTLA-4, IL-15sa, lenalidomide, celecoxib, STING-RR, or R848. Mice that did not receive a hydrogel were examined as a negative control. (A) IVIS imaging of 4T1-Luc2 cells is shown for all groups described and illustrates tumor burden.

    Science, 2018, 10(433), doi: 10.1126/scitranslmed.aar1916. Celecoxib purchased from Selleck.

    Reduced hepatic lipid contents and alleviated liver injury in EC-AMPK mice treated with selective COX-2 inhibitors. Wild-type and EC-AMPK mice given a high fat diet were treated with vehicle, celecoxib or nimesulide for a period of 4 weeks. At the end of treatment, parameters including body weight and circulating glucose (A), serum triglyceride and cholesterol levels (B were measured and presented as percentage comparisons against those from vehicle-treated wild-type mice. *P < 0.05 versus wild-type mice treated with vehicle; #P < 0.05 versus EC-AMPK mice treated with vehicle, n = 3-5.

    Br J Pharmacol 2014 171(2), 498-508. Celecoxib purchased from Selleck.

  • Breast cancer cells, wild type (WT) or anoikis resistant (AR) variants, were treated with celecoxib (CEL 5.0 uM) and/or sildenafil (SIL, 2.0 uM). Cells were isolated after 24h and viability determined by trypan blue exclusion (n = 3, +/- SEM) * p < 0.05 greater than corresponding value in vehicle control. Upper inset pictures: HCC38 cells in 96 well plates were treated with celecoxib (CEL 5.0 uM) and/or sildenafil (SIL, 2.0 uM). Cells were isolated after 24h and viability determined using a live-dead assay (red cells = dead; green cells = alive) (n = 3, +/- SEM) * p < 0.05 greater than corresponding value in vehicle control.

    J Cell Physiol 2014 10.1002/jcp.24843. Celecoxib purchased from Selleck.

    Effect of celecoxib on the in vitro proliferation of BRAFV600E and NRASQ61R melanoma cell lines. a BRAFV600E A375 and NRASQ61R SK-MEL-2 melanoma cells were seeded at the density of 3 × 103 per well in a 96-well plate and incubated with the indicated concentrations of celecoxib. Untreated cells were used as a control. DMSO (vehicle of celecoxib) concentration was maintained at 0.02% in all wells. Following a 24 h incubation at 37℃ in a 5% CO2 atmosphere, growth inhibition was determined by MTT assay. Data are expressed as mean percent of proliferation ± SD of treated cells as compared to untreated control cells. Mean percent of proliferation and SD were calculated from three independent experiments performed in triplicate. Difference between doses of celecoxib was calculated using unpaired t-test. *** indicate P < 0.001. b BRAFV600E A375 and NRASQ61R SK-MEL-2 melanoma cells were seeded at the density of 4 × 105 per well in a 75 cm2 tissue culture flask and incubated with celecoxib (60 μM). Untreated cells were used as a control. DMSO (vehicle of celecoxib) concentration was maintained at 0.02% in all wells. Following a 24 h incubation at 37℃ in a 5% CO2 atmosphere, viability of cells was determined by trypan blue assay. Data are expressed as mean percentage of viable (negative) and death cells (positive) of treated cells as compared to untreated control cells. *** indicate P < 0.001

    J Transl Med, 2017, 15(1):46. Celecoxib purchased from Selleck.

  • Oncol Lett, 2018, 16(1):317-325. Celecoxib purchased from Selleck.

Purity & Quality Control

Choose Selective COX Inhibitors

Biological Activity

Description Celecoxib is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.
Targets
COX-2 [1]
(Sf9 cells)
40 nM
In vitro

Celecoxib shows low sensitivity against COX-1 with IC50 of 15 μM. [1] Celecoxib shows an anti-proliferative effect on nasopharyngeal carcinoma (NPC) cell lines including HNE1 and CNE1-LMP1 with IC50 of 32.86 μM and 61.31 μM, respectively. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A549 MmfMSpVv[3Srb36gRZN{[Xl? MWOwMlEuOzBizszN MmnUOFghcA>? MYPpcoR2[2W|IFnDRW0uOSCneIDy[ZN{cW:wIH;uJIJwfGhicILveIVqdiCjbnSgcXJPSSCuZY\lcC=> NUnUSoI{OjZ3MUOxO|I>
H460 Mm\zSpVv[3Srb36gRZN{[Xl? NH3JdoMxNjFvM{Cg{txO MXy0PEBp NFHVR5dqdmS3Y3XzJGlESU1vMTDlfJBz\XO|aX;uJI9vKGKxdHigdJJwfGWrbjDhcoQhdVKQQTDs[ZZmdA>? NITObJYzPjVzM{G3Ni=>
HKESC-2 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzMNlDDqM7:TR?= MYO0POKhcMLi M3iwR5Nq\26rZnnjZY51dHliaX7jdoVie2W|IITo[UBKSzVywrD2ZYx2\XNib3[gc5hidGmybHH0bY7DqA>? NGnsSWQzPjR5NE[5Ny=>
CaES-17 NXW2[GJZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEP0flkzOMLizszN NHnFdog1QMLiaNMg NE\xSVJ{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczD0bIUhUUN3MNMgeoFtfWW|IH;mJI95[WyrcHzheIlvyqB? M1yxTVI3PDd2Nkmz
HKESC-2 MnHzRZBweHSxc3nzJGF{e2G7 MUWyNOKh|ryP MYC0POKhcMLi NInxW2Rz\WS3Y3XzJI95[WyrcHzheIlvNWmwZIXj[YQh[XCxcITvd4l{ M1S2dlI3PDd2Nkmz
CaES-17 MmXkRZBweHSxc3nzJGF{e2G7 MkSyNlDDqM7:TR?= NV3q[5k1PDkEoHlCpC=> Ml3rdoVlfWOnczDvfIFtcXCuYYTpck1qdmS3Y3XkJIFxd3C2b4Ppdy=> NE\yZlEzPjR5NE[5Ny=>
A549 MnPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXsUHpmPS1zNkCg{txO M3fWTlQ5yqCqwrC= Mn\mSG1UVw>? NVLiNJlvUUN3ME2xOlMvPCEQvF2= Mkj3NlY1PjR4NEO=
HCC827 M3XVTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3noOVUuOTZyIN88US=> M3mzZVQ5yqCqwrC= MVPEUXNQ NIPhPGxKSzVyPU[5MlIh|ryP M1rlW|I3PDZ2NkSz
A549 M1HhOWFxd3C2b4Ppd{BCe3OjeR?= MUm4NEDDvU1? MV:0POKhcMLi NGPDW2lFVVOR MVLpcoR2[2W|IHHwc5B1d3Orcx?= M1PUW|I3PDZ2NkSz
HCC827 MUTBdI9xfG:|aYOgRZN{[Xl? MmjGPFAhyrWP MWW0POKhcMLi NUPUSJN2TE2VTx?= M3nFVYlv\HWlZYOgZZBweHSxc3nz MnXVNlY1PjR4NEO=
SGC-7901/DDP NImwUHVHfW6ldHnvckBCe3OjeR?= NVHRcI1ROTEEoNM1US=> NWPEZ4pkOjRiaB?= M3m3PYlvcGmkaYTzJIN6[2yxb4j5[4Vv[XOnLUKgZY5lKFBvZ3z5Z49xem:2ZXnuJIV5eHKnc4Ppc44> NVXwV5h3OjZ2MEe2OVM>
SGC-7901  M4nFd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHO[HQzPMLiaNMg NVi0WppIUUN3ME2xNVUvODhizszN NUHBeXdmOjZ2MEe2OVM>
SGC-7901/DDP NWCzNmlRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWqwV3B7OjUEoHlCpC=> MUPJR|UxRTN3LkS1JO69VQ>? MYiyOlQxPzZ3Mx?=
SGC-7901/DDP M1mzOWFxd3C2b4Ppd{BCe3OjeR?= M1WwWFExyqEEtV2= MljuNlQhcA>? NEjGXWxqdmS3Y3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIIfpeIgh[2m|cHzheIlv NYG1VI1{OjZ2MEe2OVM>
SGC-7901/DDP MoPwSpVv[3Srb36gRZN{[Xl? MX[xNOKhyrWP NYXRcnJQOjRiaB?= NVvlW3dzcW6qaXLpeJMhfGinIHX4dJJme3Orb36gc4YhWC2pbInjc5Bzd3SnaX6geIhzd3WpaDDicI9kc2mwZzDFVFItKGGwZDDpcoFkfGm4YYTpcochWEuDIHHu[EBEWkWEwrC= NUjDVXkyOjZ2MEe2OVM>
SGC-7901/DDP NX;NOXhCTnWwY4Tpc44hSXO|YYm= MXuxNOKhyrWP NHHrT|EzPCCq MkPNZ4F2e2W|IHGgcYFzc2WmIHTlZ5Jm[XOnIHnuJJRp\SCuZY\lcEBw\iCEY3ytNkBxem:2ZXnu MnfmNlY1ODd4NUO=
H357 NYPGVo1XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPqV4w4NjVxMUCg{txO MXS0PEBp M3W2SWROW09? MV3pcohq[mm2czDj[YxtKGe{b4f0bOKh[2:vYnnu[YQhf2m2aDDTZYJ2fG:lbHH4 MojiNlYxODl6N{S=
TAF MUnGeY5kfGmxbjDBd5NigQ>? MUSxNOKhyrWP M1q5WFch\A>? M1;zSYFn\mWldIOgWGFHeyCjZHjld4l3\SCycn;w[ZJ1cWW| MUGyOVk5PzF{Nx?=
TAF Moe5SpVv[3Srb36gRZN{[Xl? MnWxNVDDqML3TR?= MXuzNE0yOjBibXnu MXPwc49zdHliYX\m[YN1eyCmQXv0JJBpd3OyaH;yfYxifGmxbjDjc45{\XG3ZX70JJRwKEWJRjDzbYdv[Wyrbne= MW[yOVk5PzF{Nx?=
TAF MorjSpVv[3Srb36gRZN{[Xl? M1TjOFExyqEEtV2= MUi0PEBp MWjpcoNz\WG|ZYOgSWdHWiCvUl7BJIFv\CCycn;0[YlvKGW6cILld5Nqd25? M17BPFI2QTh5MUK3
PANC-1 NIPiSoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13FUVIxNzZyL{GwNEDPxE1? M{HqclI1NzR6L{eyJIg> MmLubY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NX7wfpZUOjV7N{OwOlI>
PANC-1 NFPWTm1HfW6ldHnvckBCe3OjeR?= MlXJNlAwPjBxMUCwJO69VQ>? MVSyOEBp Mmi5ZZR1\W63YYTzJINmdGxiaX72ZZNqd25iYX7kJI1q\3KjdHnvckBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh NHPuO3czPTl5M{C2Ni=>
HeLa  MoTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fDZ|IxyqEQvF5CpC=> NFi0RmEzPMLiaB?= Ml3Y[Y5p[W6lZYOgdoFlcWG2aX;uMYlv\HWlZXSgbY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25? MlPYNlU4PzB2MkO=
SACC-83 MkTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TUWlIxyqEQvF5CpC=> MkLzNlTDqGh? M1G3SIVvcGGwY3XzJJJi\GmjdHnvck1qdmS3Y3XkJIlvcGmkaYTpc44hd2ZiY3XscEBxem:uaX\ldoF1cW:w MYGyOVc4ODR{Mx?=
HeLa  M2eyXWFxd3C2b4Ppd{BCe3OjeR?= M4\LXlIxyqEQvF5CpC=> M4H4WVI1yqCq NV\qRpZW\W6qYX7j[ZMhemGmaXH0bY9vNWmwZIXj[YQhcW6qaXLpeIlwdiCxZjDj[YxtKGGyb4D0c5Nqew>? MlPBNlU4PzB2MkO=
SACC-83 MUjBdI9xfG:|aYOgRZN{[Xl? NFvQT3ozOMLizszNxsA> MknwNlTDqGh? M3vpV4VvcGGwY3XzJJJi\GmjdHnvck1qdmS3Y3XkJIlvcGmkaYTpc44hd2ZiY3XscEBieG:ydH;zbZM> MWWyOVc4ODR{Mx?=
HeLa  NUC2bFQyTnWwY4Tpc44hSXO|YYm= NWLhOVRZOjBxNECvPFAh|ryP NETGN40zPMLiaB?= NFjTV4Z2eHKnZ4XsZZR{KFCWRV6gdIFzfGmjbHz5JIJ6KGmwaHnibZRqdmdiU4CxMEBidmRiYXP0bZZifGW|IGDUSW4h[W6mIHnuZYN1cX[jdHXzJGFMXA>? MXiyOVc4ODR{Mx?=
SACC-83 M2fFPWZ2dmO2aX;uJGF{e2G7 MmewNlAwPDBxOECg{txO NVyxeWR[OjUEoHi= NFiwWld2eHKnZ4XsZZR{KFCWRV6gdIFzfGmjbHz5JIJ6KGmwaHnibZRqdmdiU4CxMEBidmRiYXP0bZZifGW|IGDUSW4h[W6mIHnuZYN1cX[jdHXzJGFMXA>? MX2yOVc4ODR{Mx?=
HLCZ01 NV7FSoM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TjTFDjiJN4MNMgxtVO MonpOFghcA>? Mn\0SG1UVw>? Mn7CbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MmrUNlU4OjR6OUm=
HLCZ01 NWrodJZQTnWwY4Tpc44hSXO|YYm= MWW0NOKh|ryP MUWyOEBp NF\iT3VFVVOR MkPObY5kemWjc3XzJIFk[3WvdXzheIlwdiCxZjDHNE9IOS2yaHHz[UBk\WyuczDjc41jcW6nZDD3bZRpKEmITj5OtS=> NFfRdZUzPTd{NEi5PS=>
HLCZ01 NWXOeGo2SXCxcITvd4l{KEG|c3H5 M{jnd|QxyqEQvF2= MlvMNlQhcA>? Mk\ySG1UVw>? NHjZcFhmdmijbnPld{BieG:ydH;zbZMh[2:vYnnu[YQhf2m2aDDJSm4u|rF? NVHk[2VvOjV5MkS4PVk>
HLCZ01 M1TXU2Z2dmO2aX;uJGF{e2G7 NVfXT2o2PDEEoN88US=> MnzaNlQhcA>? NGqwW4tFVVOR NF\V[2JqdmO{ZXHz[ZMhXFKDSVyg[ZhxemW|c3nvckBkd22kaX7l[EB4cXSqIFnueIVz\mW{b36t{tE> NELjOWszPTd{NEi5PS=>
MGC803 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWewMVYxKM7:TR?= M2m0eFczKGh? MVTJR|UxRTR5LkK15qCKyrIkgJm2MlQ{KM7:TR?= MoLLNlU4ODF|N{i=
SGC7901 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHnNE03OCEQvF2= MoLwO|IhcA>? MYfJR|UxRTR|LkWz5qCKyrIkgJm1MlEzKM7:TR?= NHXWRnEzPTdyMUO3PC=>
MGC803 MnnYSpVv[3Srb36gRZN{[Xl? MVG0NOKh|ryP NFXLVWc5NzF4L{K0JIg> NITlPJN2eHKnZ4XsZZR{KEOkbD3iJIV5eHKnc4Ppc44> MVuyOVcxOTN5OB?=
SGC7901 NGjnUFRHfW6ldHnvckBCe3OjeR?= MWW0NOKh|ryP NInKT3k5NzF4L{K0JIg> Mm\2eZBz\We3bHH0d{BE[mxvYjDlfJBz\XO|aX;u MnPFNlU4ODF|N{i=
MCF-7  MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXqxM|ExKM7:TR?= MoDVO|IhcA>? Ml62SG1UVw>? NX24PY54\W6qYX7j[ZMh[2GuY3n0dolwdC2rbnT1Z4VlKGOnbHyg[5Jwf3SqIHnubIljcXSrb36= M1GxS|I2PjZ5NUGw
MDA-MB-231  NUf3eGpKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnKOYRZOS9zMDFOwG0> MXW3NkBp MVTEUXNQ MkW5[Y5p[W6lZYOgZ4Ft[2m2cnnvcE1qdmS3Y3XkJINmdGxiZ4Lve5RpKGmwaHnibZRqd25? MUiyOVY3PzVzMB?=
MDA-MB-231 Mo\LSpVv[3Srb36gRZN{[Xl? NXjOcVNzOC12MDFCuW0> MYe0MVI1KGh? MlP1bY5kemWjc3XzJGNQYC1{IIDyc5RmcW5iZYjwdoV{e2mxbjDpckBjd3SqIITpcYUh[W6mIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> M3T0O|I2PTh5M{K5
MCF-7 NELKSGZHfW6ldHnvckBCe3OjeR?= NI\5W3UxNTRyINM1US=> NXz1[FRCPC1{NDDo NG\qcohmdmijbnPld{B1cGViZX\m[YN1eyCxZjDUVGEhd25iQVLDS|Ih\XiycnXzd4lwdsLi NVK1SmVFOjV3OEezNlk>
MCF7-MX  MVHGeY5kfGmxbjDBd5NigQ>? NHLSdYgxNTRyINM1US=> MWK0MVI1KGh? Mn;q[Y5p[W6lZYOgeIhmKGWoZnXjeJMhd2ZiVGDBJI9vKEGEQ1eyJIV5eHKnc4Ppc47DqA>? NGL5[XkzPTV6N{OyPS=>
MDA-MB-231 MmHoSpVv[3Srb36gRZN{[Xl? MYKwMVQxKML3TR?= MWq0MVI1KGh? MnP4d5RqdXWuYYTld{B1cGViZYjwdoV{e2mxbjDv[kBCSkOJMjD1dEB1dyB2LkK3JJRqdWW|IITvJINwdnS{b3ygcIV3\WxiYomgNVIhcMLi NH\TclEzPTV6N{OyPS=>
A2780 M1TNWWZ2dmO2aX;uJGF{e2G7 M3jwSlUwOTBxMUWg{txO MnniOFghcA>? NYrKPWRM\GWlcnXhd4V{KEOxeD2yJIV5eHKnc4Ppc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NYLtbYk6OjV2MkS4PVg>
SKOV3  NXXnRnFCTnWwY4Tpc44hSXO|YYm= M3zjXlUwOTBxMUWg{txO MmjKOFghcA>? MWfk[YNz\WG|ZYOgR495NTJiZYjwdoV{e2mxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NYfPUld2OjV2MkS4PVg>
A2780 MWXGeY5kfGmxbjDBd5NigQ>? M1;keFUwOTBxMUWg{txO MYC0PEBp NWXVT2VJ\WyndnH0[ZMhfGinIHX4dJJme3Orb36gc4YhTS2lYXTo[ZJqdiCjbnSgb4Vz[XSrbh?= NFj1dlMzPTR{NEi5PC=>
SKOV3  NXjEdW9vTnWwY4Tpc44hSXO|YYm= M4TJWlUwOTBxMUWg{txO Ml:4OFghcA>? MWnlcIV3[XSnczD0bIUh\XiycnXzd4lwdiCxZjDFMYNi\GincnnuJIFv\CCtZYLheIlv MmL5NlU1OjR6OUi=
A2780 M4\QTmZ2dmO2aX;uJGF{e2G7 MXi1M|ExNzF3IN88US=> MmPYOFghcA>? M2fD[IRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBPNWOjZHjldolvKGGwZDDWbY1mdnSrbh?= M2X6NFI2PDJ2OEm4
SKOV3  NYnQ[o5rTnWwY4Tpc44hSXO|YYm= Mlj4OU8yOC9zNTFOwG0> NEfSVHk1QCCq NWPKR|hF\GWlcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKE5vY3HkbIVzcW5iYX7kJHZqdWWwdHnu NXjKdnI6OjV2MkS4PVg>
A2780 MmfJSpVv[3Srb36gRZN{[Xl? NH;zXms2NzFyL{G1JO69VQ>? Mle0NUBp MVPpcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gdE1CU1RiYX7kJJAuTVKNIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MkDDNlU1OjR6OUi=
SKOV3  MUfGeY5kfGmxbjDBd5NigQ>? NG[0foY2NzFyL{G1JO69VQ>? MnyzNUBp M374Oolv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBxNUGNVDDhcoQheC2HUlugbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MoCxNlU1OjR6OUi=
HCT-15 M1fFNGZ2dmO2aX;uJGF{e2G7 MYixNE02OCEQvF2= NH;nfJE3NTN4IHi= Moi4bY5lfWOnczD0bIUh\XiycnXzd4lwdiCxZjDDU3guOiCrbjDic5RpKGSxc3WgZY5lKHSrbXWg[IVx\W6mZX70JI1idm6nch?= NFLVVYIzPTJzOECyPC=>
HT-29  MXXGeY5kfGmxbjDBd5NigQ>? MkLTNVAuPTBizszN NYHI[VFOPi1|NjDo MlzpbY5lfWOnczD0bIUh\XiycnXzd4lwdiCxZjDDU3guOiCrbjDic5RpKGSxc3WgZY5lKHSrbXWg[IVx\W6mZX70JI1idm6nch?= M3HYN|I2OjF6MEK4
HSC3  NIDEV2RE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MnfXNQKBmzRyIN88US=> NFHQc281QCCq MU\JR|UxRTJ3LkZCtVEvPzhyIN88US=> MWiyOVE6QDd6OR?=
HSC3  M1fz[GFxd3C2b4Ppd{BCe3OjeR?= NFLsXoQzPSEQvF2= NFrzZ3A1QCCq MmLEbY5lfWOnczDhdI9xfG:|aYO= MkHoNlUyQTh5OEm=
HSC3  MVPGeY5kfGmxbjDBd5NigQ>? MnnwNlUh|ryP MYS0PEBp M{PBT4V5cGmkaYTzJJNq\26rZnnjZY51dHlicnXkeYNm\CCvaXfyZZRqd25iY3;tZolv\WRid3n0bEBETVR? NVz5WIJoOjVzOUi3PFk>
HSC3  Ml3ZSpVv[3Srb36gRZN{[Xl? M4jXN|I2KM7:TR?= MYW0PEBp NIfhPY1qdmirYnn0d{BJW0N|IHPlcIwhcW64YYPpc44h[2:vYnnu[YQhf2m2aDDDSXQ> MlnmNlUyQTh5OEm=
HSC3  Mk\3SpVv[3Srb36gRZN{[Xl? NWXJWG9JOjVizszN NYGxNohjPzJiaB?= NGG5UVhl\WO{ZXHz[ZMhVU2SLUKgZY5lKE2PUD25JJBzd3SnaX7zxsA> M3\m[FI2OTl6N{i5
201T  NVfoXHNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH71fmY4OiCq MnrLSG1UVw>? M1[4cmlEPTB;NEiuOkDDvU1? NVq5WllwOjVyNUe5OFE>
273T MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnEcpFKPzJiaB?= NV7uR4NsTE2VTx?= Ml\tTWM2OD16MD61JOK2VQ>? MWqyOVA2Pzl2MR?=
Hep-2 NGfIfmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;NWph7OzBxNUCvNVAxKM7:TR?= MX6xNk8zPC9|Nj:0PEBp NEHv[FlFVVOR MXjpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NF3lXIszPDl7OEW2OC=>
Hep-2 NFrH[JRCeG:ydH;zbZMhSXO|YYm= NELFeVQ2OCEQvF2= MkDnNE01QCCq MoTySG1UVw>? MYTpcoR2[2W|IHHwc5B1d3OrczDpckBiKHSrbXWg[IVx\W6mZX70JI1idm6nch?= NUTCOnpWOjR7OUi1OlQ>
Hep-2 NHfRcppHfW6ldHnvckBCe3OjeR?= MU[1NEDPxE1? NVTsbmx[OC12ODDo NYjRWlNKTE2VTx?= NUDVcZc5emWmdXPld{B1cGVidHXsc41memG|ZTDhZ5Rqfmm2eTDndoFlfWGubIm= NYWxPVRTOjR7OUi1OlQ>
Hep-2 MnfOSpVv[3Srb36gRZN{[Xl? M{GwelUxKM7:TR?= MYqwMVQ5KGh? MV\EUXNQ MnjI[IVkemWjc3XzJJRp\SCvUl7BJIV5eHKnc4Ppc44hd2ZiaGTFVnQ> NYT4WnZpOjR7OUi1OlQ>
SGC-7901 NYLKbXVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17TbVExNzVyL{GwNEDPxE1? M37FbFI1NzR6L{eyJIg> M{[5SmROW09? NWTIWnppcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK= M321d|I1QTl{OUW4
MKN-45 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MomyNVAwPTBxMUCwJO69VQ>? MlHqNlQwPDhxN{KgbC=> NH\aNmZFVVOR NIq4dWpqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NEH6fpczPDl7Mkm1PC=>
SGC-7901 M3nPOWZ2dmO2aX;uJGF{e2G7 M1ixOVExNzVyL{GwNEDPxE1? NWG1cGxiPDhiaB?= M3vYSmROW09? MUTkc5dvemWpdXzheIV{KHSqZTDtVm5CKGW6cILld5Nqd25ibHX2[Yx{KG:oIFPPXE0zKGGwZDDQR25CKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NUfNNVk3OjR7OUK5OVg>
MKN-45 NFfLWYdHfW6ldHnvckBCe3OjeR?= MorYNVAwPTBxMUCwJO69VQ>? MV60PEBp M3nvUGROW09? Ml30[I94dnKnZ4XsZZRmeyC2aHWgcXJPSSCneIDy[ZN{cW:wIHzleoVteyCxZjDDU3guOiCjbnSgVGNPSSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? M3jMNlI1QTl{OUW4
C666-1 NInFR|FEgXSxdH;4bYNqfHliQYPzZZk> MXeyNE05OCEQvF2= MljVNlQhcA>? M4W2eIRm[3KnYYPld{Bkd2yxbomg[o9zdWG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyxsA> MVuyOFg2PDh|OB?=
CNE-1 MnG4R5l1d3SxeHnjbZR6KEG|c3H5 NGXiSY0zOC16MDFOwG0> Moj1NlQhcA>? M3m3PIRm[3KnYYPld{Bkd2yxbomg[o9zdWG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyxsA> NV7KUIZ2OjR6NUS4N|g>
CNE-2 Mo[3R5l1d3SxeHnjbZR6KEG|c3H5 MmG5NlAuQDBizszN M2XiNlI1KGh? MW\k[YNz\WG|ZYOgZ49td267IH\vdo1ifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nctMg NVn1cHZnOjR6NUS4N|g>
C666-1 M4XmOGN6fG:2b4jpZ4l1gSCDc4PhfS=> MnLoOlAh|ryP NWPidVVoPyCm MUjlcohidmOnczDyZYRq[XSrb36gZ5l1d3SxeHnjbZR6KHSqcn;1[4ghS0:[LUKt[IVx\W6mZX70JI1idm6nch?= M3rMWFI1QDV2OEO4
CNE-1 MXHDfZRwfG:6aXPpeJkhSXO|YYm= MYW2NEDPxE1? NXKzSo9lPyCm NIHtOIJmdmijbnPld{Bz[WSrYYTpc44h[3m2b4TvfIlkcXS7IITodo92\2hiQ1;YMVIu\GWyZX7k[Y51KG2jbn7ldi=> M3LnW|I1QDV2OEO4
SNU-1041 NFH4SohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jzSVAuPDBizszN MXu0PEBp NWTxbFlEcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= NE\nSJQzPDZ7MkewNy=>
SNU-1041 NWHSUVF6TnWwY4Tpc44hSXO|YYm= M4LRWFIxNzNyIN88US=> NVHOUGw4PCCq Ml[2bY5lfWOnczDlfJBz\XO|aX;uJI9nyqCFSF;QMEBIWlB5ONMgZY5lyqC[QmCxxsBifCC2aHWgVm5CKGyndnXsxsA> MmCwNlQ3QTJ5MEO=
SNU-1041 NVrHNmZSTnWwY4Tpc44hSXO|YYm= M1vHZ|AuPDBizszN MXq0JIg> NIrSSWN2eC2{ZXf1cIF1\XNiQ1jPVOKh[W[2ZYKgeJJm[XSvZX70JJdqfGhiaHnnbEBkd26lZX70doF1cW:wcx?= MU[yOFY6OjdyMx?=
SGC-7901 M{HBR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnnOVAuOTJ3IN88US=> MofSNlQwPDhxN{KgbC=> M1zXRolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ M3PFUFI1Pjd4M{m0
SGC-7901 Mm[2RZBweHSxc3nzJGF{e2G7 MXuxNFAh|ryP NIfoT3I4OiCq MWLpcoR2[2W|IHHwc5B1d3Orcx?= MW[yOFY4PjN7NB?=
SGC-7901 M2nBdmZ2dmO2aX;uJGF{e2G7 NFe2V444PS9zMECvNVI2KM7:TR?= MX6yOE81QC95MjDo Mk\mbY5kemWjc3XzJINie3Cjc3WtPEBidmRiLUmgcXJPSSCneIDy[ZN{cW:wIHnuJIJwfGhidHnt[UBidmRiZH;z[UBu[W6wZYK= NULvXJY2OjR4N{[zPVQ>
LMeC  Mn7FSpVv[3Srb36gRZN{[Xl? NUPkenl7OjBxNUCg{txO MUG0PEBp MXzk[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gR29ZNTJicILveIVqdg>? MmPVNlQ3PTZ5NE[=
CMeC-1 NXT6WVlES2WubDDWbYFjcWyrdImgRZN{[Xl? MXyyNE82OCEQvF2= MmjXOFghcA>? NEixc|FqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NVrs[XZvOjR4NU[3OFY>
LMeC MnjWR4VtdCCYaXHibYxqfHliQYPzZZk> NEfQS4QzOC93MDFOwG0> M3ryR|Q5KGh? Mnz2bY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? Mkm2NlQ3PTZ5NE[=
CMeC-1 NID6dWlHfW6ldHnvckBCe3OjeR?= MVmyNE82OCEQvF2= NWXjUYx7PDhiaB?= NH;6S3pqdmS3Y3XzJGcyNVNiYYLy[ZN1 MlW4NlQ3PTZ5NE[=
LMeC M1j5NGZ2dmO2aX;uJGF{e2G7 MXqyNE82OCEQvF2= Mmn0OFghcA>? M4PqUYlv\HWlZYOgS|EuWyCjcoLld5Q> NYO0[phvOjR4NU[3OFY>
CMeC-1 NUjCe5RsTnWwY4Tpc44hSXO|YYm= M3G1[lIxNzVyIN88US=> M{m2NFQ5KGh? M3jmdYRm[3KnYYPld{B1cGVibHX2[Yx{KG:oIHP5Z4xqdiCGMTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MXyyOFY2Pjd2Nh?=
LMeC NEDm[2NHfW6ldHnvckBCe3OjeR?= NUDlfo5vOjBxNUCg{txO MVi0PEBp M3XaZoRm[3KnYYPld{B1cGVibHX2[Yx{KG:oIHP5Z4xqdiCGMTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M1zPS|I1PjV4N{S2
CMeC-1 MlX3SpVv[3Srb36gRZN{[Xl? M{iw[|IxNzVyIN88US=> NFjLVWc1QCCq NFf6dFhqdmS3Y3XzJINie3Cjc3WtN{Bi[3SrdnH0bY9v MkLVNlQ3PTZ5NE[=
LMeC NEHnZZRHfW6ldHnvckBCe3OjeR?= MnP6NlAwPTBizszN Mm\EOFghcA>? NXPhblJjcW6mdXPld{Bk[XOyYYPlMVMh[WO2aY\heIlwdg>? MYGyOFY2Pjd2Nh?=
OVCAR-3 MYXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NH3UbG8yOCEEtV2= NEn4XGEyKGh? M{\t[IVvcGGwY3XzJJBi[2yrdHH4[YwucW6mdXPl[EBwfmG{aXHuJINidmOncjDj[YxtKGSnYYToxsA> M{LKZ|I1PTJyMkK3
OVCAR-3 MWHBdI9xfG:|aYOgRZN{[Xl? NX61eVdNOTBiwsXN MVWxJIg> NXLS[HhOeHKxbX;0[ZMheGGlbHn0ZZhmdC2rbnT1Z4VlKGGyb4D0c5Nqe8Li NYLGVWZJOjR3MkCyNlc>
OVCAR-3 M2r4dGZ2dmO2aX;uJGF{e2G7 MXKxNEDDvU1? NYi1SpRwOSCq M1TGR4VvcGGwY3XzJJBi[2yrdHH4[YwucW6mdXPl[EBi[3SrdnH0bY9vKG:oIHPhd5Bie2VvOdMg M3zLVVI1PTJyMkK3
OVCAR-3 NYH4SY1oTnWwY4Tpc44hSXO|YYm= NUPObXU2OTBiwsXN NFLzOlAyKGh? NInhbVRld3ewLYLl[5Vt[XSnczDOSk3PwkJiYXP0bZZifGmxbjDpcoR2[2WmIHL5JJBi[2yrdHH4[Yw> NVLEdok4OjR3MkCyNlc>
OVCAR-3 MWrGeY5kfGmxbjDBd5NigQ>? NFfUfYQyOCEEtV2= M{[zNFEhcA>? MXvpcohq[mm2czDwZYNtcXSjeHXsMYlv\HWlZXSgRYt1KHCqb4PwbI9zgWyjdHnvci=> NInTUHYzPDV{MEKyOy=>
CF33 NWq0OnJHTnWwY4Tpc44hSXO|YYm= NFzXe|QyODBizszN MVSyOEBp NHy5O2ZqdmS3Y3XzJIRwf26{ZXf1cIF1cW:wIH;mJGNQYC1{IIDyc5RmcW5iZYjwdoV{e2mxbh?= MkXtNlQ2ODN5OEK=
CF33 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYexNE0yODBizszN NVPhO4lKOC12IHS= M161ZYlvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MYmyOFUxOzd6Mh?=
CF33 MUTGeY5kfGmxbjDBd5NigQ>? NUDnTnNtOTBvMUCwJO69VQ>? MXy0MVI1KGh? MmGz[IVkemWjc3XzJINmdGy|IHnuJJRp\SCVIIDoZZNmKGGwZDDpcoNz\WG|ZYOgZ4VtdHNiaX6gS|AwTzFiYYLy[ZN1 Mm\jNlQ2ODN5OEK=
LNCaP NEPz[XZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TIc|IwPS9zMDFOwG0> NH\Cd3M6PiCq Mn\1bY5pcWKrdIOgZ4VtdCCpcn;3eIghe2mpbnnmbYNidnSueTDjc41jcW6nZDD3bZRpKGG2b4L2ZZN1[XSrbh?= M3vxNlI1Ojl4OUe4
LNCaP M2rR[mFxd3C2b4Ppd{BCe3OjeR?= MXWyM|UwOTBizszN NXjzcFVXQTZiaB?= NHr5ZVBqdmS3Y3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIHH0c5J3[XO2YYTpci=> MVGyOFI6Pjl5OB?=
PC-3  NVHOeIQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoX1NE02OCEQvF2= NInxO5c1QOLCiXi= NH3qZY1qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? Ml62NlQyOjd6OEK=
PC-3  NWizOGtZS2WubDDWbYFjcWyrdImgRZN{[Xl? M1;DS|AuOTByIN88US=> M2PTe|czKGh? NWTENpdZ\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy MVSyOFEzPzh6Mh?=

... Click to View More Cell Line Experimental Data

In vivo Celecoxib exhibits a potent, oral anti-inflammatory activity. Celecoxib reduces acute inflammation in the carrageenan edema assay and chronic inflammation in the adjuvant arthritis model with ED50 of 7.1 mg/kg and 0.37 mg/kg/day, respectively. In addition, Celecoxib also exhibits analgesic activity in the Hargreaves hyperalgesia model with ED50 of 34.5 mg/kg. Besides, Celecoxib produces no acute GI toxicity in rats at doses up to 200 mg/kg and no chronic GI toxicity in rats at doses up to 600 mg/kg/day over 10 days. [1] In a C3Hf/KamLaw female mouse model, Celecoxib increases median survival time of 105 days (range, 79-145 days) after 13.5 Gy local thoracic irradiation (LTI) alone to 142 days (range, 94-155 days). [3]

Protocol

Kinase Assay:[1]
+ Expand

COX enzyme assay in vitro:

Expression of COX protein in insect cells is determined by assessing PG-synthetic capability in homogenates from cells incubated for 3 days with COX-1 or COX-2 baculovirus. Cells expressing COX-1 or COX-2 are homogenized and incubated with arachidonic acid (10 μM). COX activity is determined by monitoring PG production. No COX activity is detected in mock-infected Sf9 cells. Celecoxib are preincubated with crude 1% CHAPS homogenates (2-10 μg of protein) for 10 minutes before addition of arachidonic acid. PGE2 formed is detected by ELISA after 10 minute incubation.
Cell Research:[2]
+ Expand
  • Cell lines: HNE1 and CNE1-LMP1
  • Concentrations: 0-75 μM
  • Incubation Time: 48 hours
  • Method: The antiproliferative effect of Celecoxib on NPC cells is assessed using an MTT assay. Cells are seeded into 96-well plates and allowed to attach for 24 hours. The cells are then treated with increasing concentrations of Celecoxib (0 to 75 μM) dissolved in DMSO (final concentration ≤0.1%) and incubated for up to 48 hours. After the incubation, 20 μL of MTT dye (5 mg/mL) are added to each well and cells are incubated at 37 °C for 4 hours. After removing the supernatants, the crystals are dissolved in DMSO and the absorbance is measured at 490 nm. The half-maximal inhibitory concentration (IC50) values and the 95% confidence intervals are calculated using probit regression using SPSS 15.0 software. The experiment is performed in triplicate and repeated at least three times.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: A 0.1 mL aliquot of a 1% solution of carrageenan in 0.9% sterile saline or 1 mg of Mycobacterium butyricum in 50 μL of mineral oil is administered to the right hind foot pad of male Sprague−Dawley rats.
  • Formulation: Celecoxib is dissolved in 0.5% methyl cellulose and 0.025% Tween-20.
  • Dosages: ≤200 mg/kg
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 76 mg/mL (199.28 mM)
Ethanol 33 mg/mL (86.53 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 381.37
Formula

C17H14F3N3O2S

CAS No. 169590-42-5
Storage powder
in solvent
Synonyms SC 58635

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03590821 Not yet recruiting Healthy University of Pennsylvania November 2019 Early Phase 1
NCT03590821 Not yet recruiting Healthy University of Pennsylvania November 2019 Early Phase 1
NCT03864575 Not yet recruiting Metastatic Cancer Cliniques universitaires Saint-Luc- Université Catholique de Louvain April 15 2019 Phase 2
NCT03864575 Not yet recruiting Metastatic Cancer Cliniques universitaires Saint-Luc- Université Catholique de Louvain April 15 2019 Phase 2
NCT01344200 Not yet recruiting Pharmacokinetics of Celecoxib in Children Children''s Hospital of Eastern Ontario March 2019 Phase 4
NCT03850587 Not yet recruiting Osteoarthritis Knee Yooyoung Pharmaceutical Co. Ltd.|Green Cross Corporation March 3 2019 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I am doing an animal experiment with mice and planning to administrate S1261 via oral gavage. what are your recommendations for diluting the compound?

  • Answer:

    For oral administration, Celecoxib can be dissolved in vehicle one: "0.5% methyl cellulose and 0.025% Tween-20", or the vehicle 2 "2% DMSO/30% PEG 300/5% Tween 80/ ddH2O".

COX Signaling Pathway Map

COX Inhibitors with Unique Features

Related COX Products4

Tags: buy Celecoxib | Celecoxib supplier | purchase Celecoxib | Celecoxib cost | Celecoxib manufacturer | order Celecoxib | Celecoxib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID